Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what estimate his Department has made of the financial saving to the NHS of the policy to no longer routinely fund second stem cell transplants for blood cancer patients who have relapsed.

Decisions are taken by NHS England’s Specialised Commissioning Oversight Group that leads on the annual prioritisation process. The prioritisation process includes an impact assessment that compared the cost of a second transplant to alternative treatment pathways for relapsed disease.